For patients with metastatic colorectal cancer (mCRC) that have failed a first-line oxaliplatin-based regimen, the preferred treatment option is an irinotecan-based regimen. This prospective, observational, noncomparative, post-authorization safety study (OZONE) evaluated the safety and effectiveness of aflibercept plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) in patients with mCRC treated in daily practice after failure of an oxaliplatin-based regimen. Patients were grouped by age, renal impairment, hepatic impairment, race, number, and type of prior anticancer therapy. Of 766 treated patients enrolled, 59.5% were male, 94.8% had an Eastern Cooperative Oncology Group performance status of 0-1, all received previous chemotherapy (97.8% including oxaliplatin), and 58.6% had prior exposure to bevacizumab. At least one grade ≥ 3 treatment-emergent adverse event (TEAE) was reported in 68.3% of patients. Neutropenia, hypertension, diarrhea, and asthenia were the most frequently occurring grade ≥ 3 TEAEs. Antivascular endothelial growth factor class events were infrequent. Subgroup analyses did not reveal major differences in the safety profile according to age, renal and hepatic status, race, or prior anticancer therapy. For the total population, median overall survival was 12.5 months, median progression-free survival was 6.1 months, and overall response rate was 16.3%. Aflibercept in combination with FOLFIRI is a safe and efficacious regimen administered in current clinical practice to patients with mCRC previously treated with oxaliplatin. The study results, conducted in real-world clinical practice with a less selected patient population, are aligned with the VELOUR (NCT00561470) trial and no new safety issues were identified.

City of Hope Comprehensive Cancer Center Duarte CA 91010 USA

Hospital General Universitario Gregorio Marañón 28003 Madrid Spain

Hospital Universitario Puerta de Hierro Majadahonda 28222 Majadahonda Spain

Ividata 92300 Levallois Perret France

Miguel Servet University Hospital 50009 Zaragoza Spain

Ocala Oncology Ocala FL 34474 USA

Sanofi Cambridge MA 02139 USA

The Royal Marsden NHS Foundation Trust London and Surrey Sutton SM2 5PT UK

University Hospital Motol 150 06 Prague 5 Czech Republic

Zobrazit více v PubMed

Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. PubMed DOI

Noone A.M., Howlader N., Krapcho M. SEER Cancer Statistics Review, 1975–2015. National Cancer Institute; Bethesda, MD, USA: 2018. [(accessed on 1 February 2020)]. Based on November 2017 SEER data submission, posted to the SEER website April 2018. Available online: https://seer.cancer.gov/archive/csr/1975_2015/

Fakih M.G. Metastatic colorectal cancer: Current state and future directions. J. Clin. Oncol. 2015;33:1809–1824. doi: 10.1200/JCO.2014.59.7633. PubMed DOI

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Harborside Press, LLC,; Cold Spring Harbor, NY, USA: 2019. Colon Cancer: 2019. Version 2.

Van Cutsem E., Tabernero J., Lakomy R., Prenen H., Prausová J., Macarulla T. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 2012;30:3499–3506. doi: 10.1200/JCO.2012.42.8201. PubMed DOI

Bennouna J., Hiret S., Bouché O., Deplanque G., Borel C., François E., Conroy T., Ghiringhelli F., des Guetz G., Bennouna J., et al. Continuation of bevacizumab vs cetuximab plus chemotherapy after first progression in KRAS wild-type metastatic colorectal cancer: The UNICANCER PRODIGE18 randomized clinical trial. JAMA Oncol. 2019;5:83–90. doi: 10.1001/jamaoncol.2018.4465. PubMed DOI PMC

Bennouna J., Hiret S., Bertaut A., Bouché O., Deplanque G., Borel C. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol. 2013;14:29–37. doi: 10.1016/S1470-2045(12)70477-1. PubMed DOI

Tabernero J., Yoshino T., Cohn A.L., Obermannova R., Bodoky G., Garcia-Carbonero R. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16:499–508. PubMed

Zaltrap (ziv-aflibercept) US Prescribing Information. Sanofi-aventis U.S. LLC; Bridgewater, NJ, USA: 2012.

Sanofi . ZALTRAP© (ziv-aflibercept) Injection, Summary of Product Characteristics. EMA; Amsterdam, The Netherlands: 2017.

Kennedy-Martin T., Curtis S., Faries D., Robinson S., Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16:495. doi: 10.1186/s13063-015-1023-4. PubMed DOI PMC

Carroll R., Ramagopalan S.V., Cid-Ruzafa J., Lambrelli D., McDonald L. An analysis of characteristics of post-authorisation studies registered on the ENCePP EU PAS Register. F1000Research. 2017;6:1447. doi: 10.12688/f1000research.12198.1. PubMed DOI PMC

Cohen A.T., Goto S., Schreiber K., Torp-Pedersen C. Why do we need observational studies of everyday patients in the real-life setting? Eur. Heart J. 2015;17:D2–D8. doi: 10.1093/eurheartj/suv035. DOI

Booth C.M., Tannock I.F. Randomised controlled trials and population-based observational research: Partners in the evolution of medical evidence. Br. J. Cancer. 2014;110:551–555. doi: 10.1038/bjc.2013.725. PubMed DOI PMC

Fernández Montes A., Martínez Lago N., Covela Rúa M., de la Cámara Gómez J., González Villaroel P., Méndez Méndez J.C. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers. Cancer Med. 2019;8:882–889. doi: 10.1002/cam4.1903. PubMed DOI PMC

Ivanova J.I., Saverno K.R., Sung J., Duh M.S., Zhao C., Cai S. Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA. Med. Oncol. 2017;34:193. doi: 10.1007/s12032-017-1049-4. PubMed DOI PMC

Feliu J., de Corcuera I.D., Manzano J.L., Valladares-Ayerbes M., Alcaide J., García T.G. Effectiveness and safety of aflibercept for metastatic colorectal cancer: Retrospective review within an early access program in Spain. Clin. Transl. Oncol. 2017;19:498–507. doi: 10.1007/s12094-016-1556-3. PubMed DOI

Pastorino A., Di Bartolomeo M., Maiello E., Iaffaioli V., Ciuffreda L., Fasola G. Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. Clin. Colorectal. Cancer. 2018;17:e457–e470. doi: 10.1016/j.clcc.2018.03.002. PubMed DOI

Gouverneur A., Claraz P., Rousset M., Arnaud M., Fourrier-Réglat A., Pariente A. Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: A Study Using the International Pharmacovigilance Database. Target Oncol. 2017;12:805–814. doi: 10.1007/s11523-017-0529-y. PubMed DOI

Tabernero J., Van Cutsem E., Lakomý R., Prausová J., Ruff P., Van Hazel G.A. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial. Eur. J. Cancer. 2014;50:320–331. doi: 10.1016/j.ejca.2013.09.013. PubMed DOI

Zobrazit více v PubMed

ClinicalTrials.gov
NCT00561470